FDA approves BridgeBio’s heart disease drug, setting up competition with Pfizer, Alnylam – Endpoints News

The FDA approved BridgeBio’s ​​acoramidis in a rare, genetic heart disease that’s expected to become an intense area of market competition, and a broad label will give it a near-immediate boost against the current leader.

#stockmarket #breaking

Leave a Reply

WP Twitter Auto Publish Powered By : XYZScripts.com